CNS-Diagnostics: Chimera Biotec Starts Study on Novel Biomarker Detection for Alzheimer's Disease
European Commission supports study including 11 centres from 6 European countries
Abnormalities in the processing of the beta amyloid protein are an important characteristic of Alzheimer's disease. Moreover, recent studies have shown that beta amyloid precursor oligomers play an important role in the early stage of Alzheimer's disease.
"To describe and characterize these oligomers will be one of the most important advancements in the understanding of Alzheimer's disease in the next years" summarizes Jan Detmers, Chimera Biotec´s Business Development Director. Currently, many companies develop drugs that influence the processing of the beta amyloid peptide and its precursors. In this study, it will be investigated whether the oligomers can be used as a diagnostic marker of Alzheimer's disease and whether it can be used to measure the effect of drug treatments.
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.